AVDL - Avadel Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.96
-0.10 (-1.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close8.06
Open8.07
Bid7.52 x 1400
Ask8.30 x 800
Day's Range7.88 - 8.27
52 Week Range1.53 - 13.49
Volume510,924
Avg. Volume907,361
Market Cap462.707M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.55
Earnings DateAug 07, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Avadel Pharmaceuticals plc (AVDL) Q1 2020 Earnings Call Transcript
    Motley Fool

    Avadel Pharmaceuticals plc (AVDL) Q1 2020 Earnings Call Transcript

    It is now my pleasure to introduce your host Tom McHugh, Chief Financial Officer. As a reminder before we begin the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.

  • Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1
    Zacks

    Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1

    Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.

  • GlobeNewswire

    Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results

    Reported positive topline data from the pivotal Phase 3 REST-ON studyStrengthened balance sheet with $190 million in gross proceeds from a private placement in February 2020 and.

  • Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
    Motley Fool

    Why Jazz Pharmaceuticals' Symphony of Growth Is About to End

    Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.

  • Jazz Pharmaceuticals (JAZZ) Q1 2020 Earnings Call Transcript
    Motley Fool

    Jazz Pharmaceuticals (JAZZ) Q1 2020 Earnings Call Transcript

    JAZZ earnings call for the period ending March 31, 2020.

  • GlobeNewswire

    Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2020. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. Avadel Pharmaceuticals plc (AVDL) is an emerging biopharmaceutical company.

  • GlobeNewswire

    Avadel Pharmaceuticals Announces Pricing of Public Offering

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today the pricing of an underwritten public offering of 11,630,000 ordinary shares, in the form of American Depositary Shares (“ADSs”) at a price to the public of $10.75 per ADS. All of the ADSs are being offered by Avadel. In connection with the public offering, Avadel has granted the underwriters a 30-day option to purchase up to an additional 1,744,500 ADSs at the public offering price less the underwriting discounts and commissions.

  • Is a Beat in Store for Avadel (AVDL) This Earnings Season?
    Zacks

    Is a Beat in Store for Avadel (AVDL) This Earnings Season?

    On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.

  • Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?
    Motley Fool

    Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?

    Will a small change in a drug's method of delivery be enough to generate over $1 billion in new sales?

  • The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
    Benzinga

    The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Avadel Pharmaceuticals PLC (NASDAQ: AVDL) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * BioSig Technologies Inc (NASDAQ: BSGM) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Cytosorbents Corp (NASDAQ: CTSO) * DexCom, Inc. (NASDAQ: DXCM) * Erytech Pharma SA (NASDAQ: ERYP) * Exelixis, Inc. (NASDAQ: EXEL) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * I-Mab ADR (NASDAQ: IMAB) * Imara Inc (NASDAQ: IMRA) * Incyte Corporation (NASDAQ: INCY) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * Keros Therapeutics Inc (NASDAQ: KROS) * Masimo Corporation (NASDAQ: MASI) * Novo Nordisk A/S (NYSE: NVO) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Quidel Corporation (NASDAQ: QDEL) * REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) * Repligen Corporation (NASDAQ: RGEN) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Translate Bio Inc (NASDAQ: TBIO) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * Vaxart Inc (NASDAQ: VXRT) * Vermillion, Inc. (NASDAQ: VRML) * West Pharmaceutical Services Inc. (NYSE: WST) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) * Zynex Inc. (NASDAQ: ZYXI)None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Monday.Stocks In Focus Syndax Presents Positive Pre-clinical & Clinical Data For Blood Cancer Drug Syndax Pharmaceuticals Inc (NASDAQ: SNDX) presented positive preclinical and initial clinical data for SNDX-5613, its potent, highly selective oral menin inhibitor, with the data suggesting the investigational asset can induce response in patients with genetically-defined acute leukemias."Notably, clinical activity was achieved rapidly after a single, 28-day cycle, a highly encouraging sign in this population of patients who face a particularly poor prognosis with few effective treatment options," said Briggs Morrison, CEO of Syndax.The company said it will present additional findings from this trial in the fourth quarter.It also said SNDX-5613 was recently granted Orphan Drug Designation for the treatment of adult and pediatric acute myeloid leukemia.In after-hours trading, Syndax shares added 20.33% to $13.85.Moderna Files IND Application For Phase 2 Study of Coronavirus Vaccine Moderna Inc (NASDAQ: MRNA) said it has submitted an IND application to the FDA for its mRNA vaccine candidate mRNA-1273 against the novel coronavirus - SARS-CoV-2 - for evaluating it in a Phase and late-stage studies if supported by the Phase 1 study conducted by the National Institute of Allergy and Infectious Diseases.The company expects the study to begin in the second quarter.The stock gained 7.18% to $51.50 in after-hours trading.Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, InovioRoche Reports Positive Results For Pivotal Study of its Spinal Muscular Dystrophy Treatment Roche Holdings AG's Basel (OTC: RHHBY) presented data from FIREFISH Part 2 - a pivotal global study that is evaluating its risdiplam in infants, ages 1-7 months, with symptomatic Type 1 spinal muscular atrophy, which showed the primary endpoint was met. The company noted that 29% of infants could sit without support for five seconds by month 12, as assessed by the Gross Motor Scale of Bayley Scales of Infant and Toddler Development Third Edition.View more earnings on PFEAdditionally, the company noted that 43.9% of infants were able to hold their head upright, 31.7% were able to roll to the side and 4.9% infants were able to stand with support.Risdiplam is an orally administered survival motor neuron-2 splicing modifier for SMA.Roche is leading the development of risdiplam and is working with the SMA Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT) on this.The regulatory application for the investigational asset was accepted with priority designation by the FDA, with an expected PDUFA date of Aug. 24.Separately, Roche also released new analyses of Phase 3 OPERA I and OPERA II studies as well as open-label extensions, of its Ocrevus, which showed the treatment reduced the risk of disease and disability progression in relapsing multiple sclerosis and primary progressive multiple sclerosis.Avadel to Offer $100M Worth of ADSs Avadel Pharmaceuticals PLC (NASDAQ: AVDL) said it commenced an underwritten public offering of $100 million shares, in the form of ADSs. All the ADSs are being offered by Avadel.The stock slipped 0.90% to $11.05 in after-hours trading.Earnings Novartis AG's (NYSE: NVS) first-quarter net sales from continuing operations rose 11% to $12.28 billion, EPS climbed 19% to 96 cents and core EPS increased 29% to $1.56, ahead of the $1.36 per share consensus estimate. The company expects 2020 sales to grow mid- to high-single digits and core operating income to increase in high-single to low-double digits.The stock added 0.90% to $90.40 in after-hours trading.On The Radar Clinical Readouts Iovance Biotherapeutics Inc (NASDAQ: IOVA) is scheduled to present at the American Association for Cancer Research, or AACR, 2020 Virtual Annual Meeting Phase 1 data for tumor-infiltrating lymphocytes in non-small cell lung cancer.Earnings Merck & Co., Inc. (NYSE: MRK) (Q1 Revenues of $12.1 billion, up 11%, and non-GAAP EPS $1.50 Vs. consensus of $11.46 billion and $1.34; lowered full-year guidance)Pfizer Inc. (NYSE: PFE) (Q1 Revenues of $12 billion, down 7%, and adjusted EPS of 80 cents Vs. consensus of $11.87 billion and 73 cents; reaffirmed 2020 guidance)See more from Benzinga * The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight * BioNTech, Immunic Soar On COVID-19 Developmental Updates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it is commencing an underwritten public offering of $100 million in ordinary shares, in the form of American Depositary Shares (“ADSs”). All of the ADSs are being offered by Avadel. In connection with the offering, Avadel intends to grant the underwriters a 30-day option to purchase up to an additional $15 million in ADSs at the public offering price less the underwriting discounts and commissions.

  • This Top-Ranked Biotech Stock Touched A 4-Year High — Here's Why
    Investor's Business Daily

    This Top-Ranked Biotech Stock Touched A 4-Year High — Here's Why

    Avadel Pharmaceuticals stock rocketed Monday after the biotech company said its narcolepsy treatment succeeded in a Phase 3 test. The drug is a once-nightly form of sodium oxybate.

  • Benzinga

    A Look Into Avadel Pharmaceuticals' Price Over Earnings

    In the current session, Avadel Pharmaceuticals Inc. (NASDAQ: AVDL) is trading at $12.95, after a 31.74% increase. Over the past month, the stock increased by 63.60%, and in the past year, by 939.20%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently above from its 52 week high by 20.47%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 7.57 in the specialty & generic drug manufacturers industry, Avadel Pharmaceuticals has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may be unable to attain key insights from trailing earnings.See more from Benzinga * Morning Market Stats in 5 Minutes * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

    The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically significant (p<0.001), and clinically meaningful improvement across all.

  • Avadel's Shares March Higher, Can It Continue?
    Zacks

    Avadel's Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

  • Is Avadel Pharmaceuticals (AVDL) Stock a Solid Choice Right Now?
    Zacks

    Is Avadel Pharmaceuticals (AVDL) Stock a Solid Choice Right Now?

    Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock Options
    Zacks

    Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock Options

    Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.

  • GlobeNewswire

    Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it has completed the REST-ON Phase 3 clinical trial for FT218. The REST-ON study enrolled a total of 212 patients, and the last patient last visit occurred earlier this week. The Company currently expects to announce topline data from the study in the second quarter of 2020.

  • Avadel Pharmaceuticals plc Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
    Simply Wall St.

    Avadel Pharmaceuticals plc Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

    Shareholders in Avadel Pharmaceuticals plc (NASDAQ:AVDL) had a terrible week, as shares crashed 39% to US$6.01 in the...

  • Does Market Volatility Impact Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Share Price?

    If you own shares in Avadel Pharmaceuticals plc (NASDAQ:AVDL) then it's worth thinking about how it contributes to the...

  • GlobeNewswire

    Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2020Raised $65 million in gross proceeds from private placement with leading.

  • ACCESSWIRE

    Avadel Pharmaceuticals Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Avadel Pharmaceuticals Plc (NASDAQ:AVDL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at ...

  • 5 Safe-Haven Stocks to Buy on Broader Market Weakness
    Kiplinger

    5 Safe-Haven Stocks to Buy on Broader Market Weakness

    A wide investor search is on for safe-haven stocks to buy.We've plunged into a stock market correction that's nearing bear-market territory amid escalating coronavirus fears and a potential oil-price war. Some of the headline numbers have been eye-popping. The S&P; 500 Index dropped roughly 18% in the course of two weeks - something it took nearly two months to do during the near-bear market in the fourth quarter of 2018. And oh, the volatility. The index has endured eight moves of 3% or more (in either direction) since Feb. 20, 2020. The last one before that came on Jan. 4 ... of 2019.Goldman Sachs analysts are calling for the end of the current bull market: "We believe the S&P; 500 bull market will soon end," they write, projecting another 15% decline in stocks from here. However, Merrill Lynch strategists, led by Savita Subramanian, believe investors shouldn't panic-sell all of their holdings, arguing that while stocks will feel the effects, a bear market isn't imminent. "Negative headlines and panic selling are not good reasons to sell, but the coronavirus outbreak is now meaningfully impacting fundamentals," the firm writes.This brutal market environment has investors seeking out "safe havens" - investments that are relatively more insulated if economic conditions worsen. Many safe-haven stocks boast products that people need regardless of the economic landscape (think health care, utilities and consumer staples). However, as the broader market finds itself further mired in the downturn, pinpointing the tickers that can hold up strong in the long run isn't easy. That's where TipRanks comes in.Here are five save-haven stocks to buy on the current weakness. Using TipRanks' Stock Screener tool, we were able to zero in on five stocks the analyst community widely believes can maintain their bearings amid heightened levels of volatility. No stock is perfectly safe, but these companies are widely expected to come out on the other side better off than their peers. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio

  • 3 “Strong Buy” Stocks Holding Steady Amid Coronavirus Concerns
    TipRanks

    3 “Strong Buy” Stocks Holding Steady Amid Coronavirus Concerns

    Coronavirus fears have weighed heavily on the market, and investors are seeking refuge. While the situation in China is reportedly improving, health officials warn the spike in new cases throughout the rest of the world underscores the risk of a global pandemic. These statements have rattled financial markets; in the last five days alone, the S&P 500 and NASDAQ indexes have shed 8% and 9% of their value, respectively.Against this backdrop, Wall Street pros remind investors not to panic and rush to a sell-off, pointing out that a select group of tickers still represent compelling opportunities. So, as the broader market plunges, how are investors supposed to find the stocks that are standing strong?Using TipRanks’ Stock Screener tool, we were able to lock in on 3 stocks that have held their own amid the public health crisis. Not only has each been assigned enough bullish ratings to earn a “Strong Buy” analyst consensus, but all of the names also boast plenty of upside potential. Let’s dive in.iClick Interactive Asia Group (ICLK)As an independent online marketing and enterprise data solutions company, iClick enables marketers from all over the world to reach consumers in China. The Hong Kong-based name provides customers with a proprietary platform featuring omni-channel capabilities to meet all of their marketing needs. While coronavirus concerns wreak havoc on the market, ICLK has gained 45% year-to-date, a fact that hasn’t gone unnoticed by the Street.Jeffries analyst Thomas Chong believes that its machine learning and AI-based technology have helped it cement its status as one of the leading marketing technology companies in China. Thanks to its “one-stop shop solution” for both user engagement and acquisition as well as vast consumer data, the company has been able to partner with over 114,000 mobile apps and 2.1 million websites in China, including Tencent which is a platinum partner.With Tencent accounting for 60% to 70% of the company’s gross billings, Chong sees it as potentially fueling significant growth for ICLK. “We estimate marketing solution revenue to grow at 20% year-over-year and 18% year-over-year in 2019 and 2020, benefiting from the secular trend of Tencent’s social advertising. We consider iClick as an independent marketing technology player benefiting from the unique marketing environment in China due to relatively fragmented market share among different internet players vs overseas,” he explained.Additionally, Chong cites its investment in enterprise solutions as being encouraging, arguing that while ICLK may incur losses as a result, the efforts will pay off in the long run. “In 2019, iClick has been stepping up efforts in enterprise solutions on smart retail through Tencent’s mini-programs… We estimate revenue from enterprise solutions to increase from about $10 million in 2019 to $24 million in 2020 and $50 million in 2021, with the number of customers to increase from 30 in 2019 to 60 in 2020,” he stated.In line with his optimistic outlook, Chong started his ICLK coverage by publishing a Buy rating. At $7.96, his price target implies shares could climb 71% higher in the next twelve months. (To watch Chong’s track record, click here)Looking at the consensus breakdown, it has been relatively quiet when it comes to other analyst activity. That being said, the two other analysts covering the stock see it as a Buy, making the consensus rating a Strong Buy. The $7.82 average price target puts the upside potential at 68%. (See iClick stock analysis on TipRanks)Avadel Pharmaceuticals (AVDL)Avadel Pharmaceuticals is focused on developing solutions to address the unmet needs of patients. In addition to its three products already on the market and its development candidate, AVDL is up 37% since the beginning of 2020, making it a stand-out among analysts.Part of the excitement is related to its FT218 candidate. The company’s lead investigational asset, which is in Phase 3 development, was designed as a sodium oxybate formulation for once-nightly use and features patented Micropump technology for extended-release oral suspension to treat excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients. Previously, management announced that the FDA allowed it to amend the statistical analysis plan (SAP) under the special protocol assessment agreement (SPA). As a result, the company can use a smaller sample size.Ladenburg Thalmann’s Matthew Kaplan points out that this pushed the enrollment completion and REST-ON study data readout timeline forward by about twelve months. As enrollment closed in December, top-line data is expected to be released in Q2 2020. According to Kaplan, this data could support an NDA in the second half of this year as well as possible approval in 2021. Should the candidate receive the go ahead, the four-star analyst believes that it would be superior to the current standard-of-care.To this end, Kaplan recommends investors snap up shares before the REST-ON Phase 3 study readout. “We believe that the majority of the value of AVDL is the FT218 program which has completed enrollment and on track to read out in 2Q20...Given the FT218 pharmacokinetic profile, which was detailed at the Annual Meeting of the Associated Professional Sleep Societies during June 2019 and was also highlighted at the World Sleep Congress in late September 2019, combined with the known efficacy profile of sodium oxybate, we believe there is a high probability of success for the REST-ON pivotal study,” he commented.It should come as no surprise, then, that Kaplan stayed with the bulls, reiterating his Buy call. Adding to the good news, the analyst also bumped up his price target from $8 to $14, implying 35% upside potential. (To watch Kaplan’s track record, click here)Like iClick, Avadel has received 3 Buy ratings vs no Holds or Sells in the last three months, and thus, the consensus rating comes in as a Strong Buy. Not to mention the $14.33 average price target brings the upside potential to 38%. (See Avadel stock analysis on TipRanks)Novavax (NVAX)Biotech company Novavax uses proprietary recombinant nanoparticle vaccine technology to develop vaccine candidates, most recently announcing that it’s advancing an experimental coronavirus vaccine. With this welcome piece of good news pushing shares 132% higher since the year’s start, it’s no wonder Wall Street focus has zeroed in.On February 26, Novavax revealed that it plans to initiate human testing for two or more novel COVID-19 vaccine candidates in either May or June. Currently, several nanoparticle vaccine candidates are being studied in animal models before the ideal candidate is selected. As the company only began development on January 10, the announcement was a pleasant surprise for the analyst community.Michael Higgins of Ladenburg Thalmann highlights its technology which uses both its insect-based vaccine platform and its novel Matrix-M adjuvant as making it the ideal player to combat the coronavirus. Additionally, while some have questioned if a vaccine will be an effective course of action for coronavirus, the analyst believes that a vaccine will be necessary.“We highly doubt this flu outbreak goes away largely on its own since some patients with the prior viruses were highly symptomatic and quarantined, while many developing COVID-19 are contagious before being sick enough to be quarantined,” he explained. Higgins doesn’t dispute the fact that there are other possible drug treatments for COVID-19, including remdesivir from Gilead, but argues that this doesn’t eliminate the need for a vaccine. Additionally, as Novavax has already shown it can produce a safe and effective vaccine against MERS-CoV, the analyst stated “investors are right to buy up NVAX shares” following the February 26 news.Bearing this in mind, Higgins maintained a Buy recommendation and $27.50 price target. This target conveys his confidence in NVAX’s ability to soar 198% over the next year. (To watch Higgins’ track record, click here)What does the rest of the Street think about NVAX’s prospects? It turns out that they also have high hopes for the biotech. With 100% Street support, or 4 Buys to be exact, the message is clear: the stock is a Strong Buy. At 17.38, the average price target suggests 89% upside potential. (See Novavax stock analysis on TipRanks)